The Quintis shareholder class action trial could be delayed for almost two years, while ASIC runs its civil proceedings case against the founder of the sandalwood oil production company.
GSK, Pfizer merger won’t cause Nurofen maker any pain, ACCC says
The Australian Competition and Consumer Commission has signed off on pharmaceutical giant GlaxoSmithKline’s proposed acquisition of fellow heavyweight Pfizer, a merger which will put pain medications Panadol, Voltaren and Advil all under one roof, with the competition cop saying Nurofen maker Reckitt will still be able to compete.